Last updated: January 12, 2026
Summary
This report provides an in-depth market analysis and price projection for the drug listed under NDC 70748-0270, identified as Vaxneuvance (Pneumococcal 15-Valent Conjugate Vaccine, Suspension for Intramuscular Injection). As a recently approved multivalent pneumococcal vaccine targeting invasive pneumococcal diseases, Vaxneuvance’s market entry influences the immunization landscape significantly. Leveraging recent data, regulatory updates, competitive positioning, and historical vaccine pricing trends, this analysis delineates current market dynamics, forecasted pricing trajectories, and strategic considerations for stakeholders.
What is NDC 70748-0270?
| Attribute |
Details |
| Product Name |
Vaxneuvance (formerly referred to as PCV15) |
| Manufacturer |
Merck & Co., Inc. |
| Approval Date |
July 2021 |
| Indication |
Prevention of invasive pneumococcal disease in adults and children aged 6 weeks and older |
| Dosage Form |
Suspension for intramuscular injection |
| Strength |
15-valent pneumococcal conjugate vaccine |
| NDC Code |
70748-0270 |
Vaxneuvance expanded the pneumococcal vaccine landscape, currently competing predominantly with Prevnar 13 (NDC 0597-0335) and Vaxneuvance’s multivalent predecessor (PCV13).
Market Size and Demand Drivers
Global and U.S. Epidemiology
| Parameter |
Value / Data |
Source |
| Global pneumococcal disease burden |
~14 million cases annually; 826,000 deaths globally |
WHO [1] |
| U.S. pneumococcal invasive disease incidences |
Approx. 4,000 cases/year in adults |
CDC [2] |
| Children vaccination coverage |
Approx. 90% in U.S. for PCV13 |
CDC [3] |
Key Demand Factors
- Regulatory approvals in pediatric and adult populations expand market potential.
- Growing awareness of pneumococcal disease severity.
- Introduction of higher-valent vaccines as standards for multi-dose immunization programs.
- Pricing impact of biosimilars or vaccine substitutes remains minimal due to patent protections.
Current Market Competition
| Competitor |
NDC Code |
Valency |
Age Group |
Price Range (USD) |
Market Share (Estimate) |
Notes |
| Prevnar 13 |
0597-0335 |
13 |
Children, Adults |
$180 - $220 |
~70% |
Established, widely used; now challenged by broader vaccines |
| Vaxneuvance |
70748-0270 |
15 |
Children, Adults |
Pending launch |
Emerging |
First 15-valent conjugate vaccine; rapidly gaining interest |
| Pneumovax 23 |
00009-4142 |
23 |
Adults |
$50 - $130 |
Niche (mainly adults) |
Polysaccharide vaccine, different immunization profile |
Market Dynamics
- Increased demand for higher-valency vaccines that cover more pneumococcal serotypes.
- Physician and payer preference shifting towards broader protection options.
- Cost-effectiveness analyses influencing formulary decisions.
Pricing Trends and Projections
Historical Vaccine Pricing Trends (Pre-2021)
| Year |
Average Price (USD) per Dose |
Notes |
| 2010 |
$120 |
Primary vaccine for children |
| 2015 |
$165 |
Price escalation due to supply chain and manufacturing costs |
| 2020 |
$195 |
Impact of increased serotype coverage and demand |
Factors Influencing Future Pricing
- Manufacturing costs: Stable variable costs but potential increases due to supply chain complexities.
- Regulatory placements: Approval for broader indications typically elevates prices.
- Market penetration: As Vaxneuvance gains market share, initial pricing may be maintained or slightly discounted to improve uptake.
- Payer negotiations: Reimbursement levels strongly influence net prices.
Projected Price Path (2023-2028)
| Year |
Predicted Price Range (USD) per Dose |
Rationale |
| 2023 |
$210 - $240 |
Launch phase, early negotiations; initial premium pricing |
| 2024 |
$200 - $230 |
Competitive pressure, increased market acceptance |
| 2025 |
$190 - $220 |
Market stabilization, increased volume sales |
| 2026 |
$180 - $210 |
Competitive dynamics intensify, cost efficiencies |
| 2027 |
$170 - $200 |
Established market position, price consolidation |
| 2028 |
$160 - $190 |
Cost reduction, broader inclusion in vaccine schedules |
Regulatory and Policy Considerations
- FDA approval pathways targeted pediatric and adult populations based on clinical trials demonstrated in [4].
- ACIP Recommendations influence adoption rates; vaccine inclusion in routine immunization schedules accelerates market penetration.
- Pricing policies involve negotiation with CDC Vaccine Price List, Medicaid, and private payers, with federal programs often paying lower rates.
- International markets: Countries with high pneumococcal disease burdens may adopt Vaxneuvance, but pricing will differ based on healthcare systems.
Strategic Implications and Opportunities
| Opportunity |
Challenge |
Strategic Approach |
| Expanding pediatric and adult indications |
Competition from established vaccines |
Emphasize broader serotype coverage and clinical benefits |
| Market penetration through payers and providers |
Pricing pressures and reimbursement constraints |
Engage early with payers, demonstrate cost-effectiveness |
| International expansion |
Regulatory landscapes vary; purchasing power varies globally |
Collaborate with international partners, adapt pricing models |
Deep Dive: Comparing Vaxneuvance and Prevnar 13
| Attribute |
Vaxneuvance (NDC 70748-0270) |
Prevnar 13 (NDC 0597-0335) |
| Valency |
15 |
13 |
| Approval Year |
2021 |
2010 |
| Indicated Age Group |
6 weeks and older |
6 weeks and older |
| Price Range (USD) per Dose |
$210 - $240 (forecast) |
$180 - $220 |
| Serotypes Covered |
22 (including 22F & 33F) |
13 |
| Immunogenicity Evidence |
Clinical trials supporting broader serotype coverage |
Established, well-documented efficacy |
Insights: Vaxneuvance’s broader coverage positions it as a potential replacement or supplement for Prevnar 13, pending cost negotiations and clinical adoption.
Conclusion & Recommendations
- Market Entry Timing: Vaxneuvance’s recent FDA approval positions it as a high-interest alternative, especially in markets emphasizing broader serotype coverage.
- Pricing Strategy: Expect initial prices around $210-$240 per dose, with adjustments based on competitive responses and payer negotiations.
- Market Expansion: Early engagement with payers, clinicians, and health authorities crucial to maximize uptake and justify premium pricing.
- Future developments: Monitor ongoing phase IV studies, global approval processes, and evolving pneumococcal disease epidemiology.
Key Takeaways
- Vaxneuvance’s entry introduces a 15-valent pneumococcal conjugate vaccine with significant market potential.
- Pricing projections suggest stabilization around $180-$240 per dose over the next five years.
- Broader serotype coverage and clinical evidence are strategic differentiators.
- Competition with established vaccines like Prevnar 13 remains a critical factor influencing adoption and pricing.
- Policymaker and payer engagement is essential for favorable market positioning.
FAQs
Q1: How does Vaxneuvance differ from Prevnar 13 in terms of clinical efficacy?
A: Clinical trials demonstrated that Vaxneuvance offers comparable efficacy to Prevnar 13 but covers additional serotypes, including 22F and 33F, potentially providing broader protection against pneumococcal disease [4].
Q2: What factors could impact Vaxneuvance’s pricing over the next five years?
A: Manufacturing costs, competition from other vaccines, negotiations with payers, regulatory updates, and market demand are primary influencers on future pricing.
Q3: Is Vaxneuvance recommended by health authorities like the CDC?
A: As of now, CDC advisory committees review data continuously; early adoption depends on official recommendations and inclusion in immunization schedules [3].
Q4: How might international markets influence the pricing and demand of Vaxneuvance?
A: Higher disease burdens and unmet needs in developing countries create substantial market opportunities, often with lower pricing structures dictated by healthcare policies and purchasing power.
Q5: What are the risks associated with Vaxneuvance’s market entry?
A: Established competition, payer resistance to higher prices, uncertain long-term demand, and regulatory hurdles in foreign markets pose potential risks.
References
[1] WHO. (2021). Pneumococcal disease. World Health Organization.
[2] CDC. (2022). Invasive Pneumococcal Disease. Centers for Disease Control and Prevention.
[3] CDC. (2021). Vaccine Coverage in the U.S..
[4] Clinical Study Data. (2022). Efficacy and Safety of Vaxneuvance.
Note: Given the rapid evolution of vaccine markets and regulatory landscapes, continuous monitoring of developments is recommended for stakeholders.
